Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31091386 | 0.87 | TLR2 (0.51) | TLR2CASP3TNFKMT2AMDM4 | |
| SCHEMBL14047810 | 0.87 | CASP3 (0.51) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL16327986 | 0.86 | TLR2 (0.59) | TLR2TNF | |
| SCHEMBL30229906 | 0.86 | TLR2 (0.51) | TLR2CASP3TNFKMT2AMDM4 | |
| SCHEMBL27353254 | 0.86 | TLR2 (0.51) | TLR2CASP3TNF | |
| SCHEMBL27353661 | 0.86 | TLR2 (0.51) | TLR2CASP3TNF | |
| SCHEMBL29907904 | 0.85 | CASP3 (0.55) | TLR2CASP3TNFKMT2AMDM4 | |
| SCHEMBL13038830 | 0.85 | CASP3 (0.51) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL27353250 | 0.84 | TLR2 (0.59) | TLR2TNF | |
| SCHEMBL30854410 | 0.83 | MDM4 (0.57) | CASP3KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | disclosed |
| US-7824687-B2 | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2010006343-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, MICA, SIGLEC7 | TLR2 1707/4885CASP3 3088/4885TNF 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.